Blockchain Registration Transaction Record

HeartBeam Joins EU-Funded EXIT-CVD to Study Portable ECG

HeartBeam joins EU-funded EXIT-CVD initiative to study its portable ECG system for early cardiac event detection. FDA Breakthrough Device designated.

This news underscores the growing importance of decentralized cardiac care and early detection technologies. Heart attack and acute coronary syndrome remain leading causes of death worldwide, and many patients face high risk of recurrence after discharge. HeartBeam’s portable 3D ECG system could enable timely intervention outside hospitals, potentially saving lives and reducing healthcare costs. Participation in a large EU-funded consortium validates the technology and provides robust clinical evidence that could accelerate adoption and regulatory approvals. For investors, this collaboration highlights HeartBeam’s strategic positioning in the cardiac monitoring market and its potential to capture a significant share of the expanding remote patient monitoring sector. As cardiovascular diseases continue to burden healthcare systems globally, innovations like HeartBeam’s are critical to improving outcomes and efficiency.